Avivo Biomedical Inc. Appoints Rob Carroll MD as Chief Medical Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)--Avivo Biomedical Inc. (‘Avivo’, avivobio.com), a leading innovator in blood type conversion for organ transplantation and blood transfusion applications, is pleased to announce the appointment of Rob Carroll MD, DM (Oxon), FRACP, A(ACHI) as its new Chief Medical Officer (CMO).

“Dr. Carroll’s appointment marks a significant milestone for Avivo as we continue to push the boundaries of what’s possible in organ transplantation and biomedical innovation”

Dr. Rob Carroll brings an extraordinary depth of expertise to Avivo, combining over two decades of leadership in transplant medicine, nephrology, and immunogenetics. As a transplant physician, nephrologist, and American Society of Immunogenetics and Histocompatibility certified HLA lab director, Dr. Carroll has been at the forefront of groundbreaking advancements in the field. Notably, he was a key member of the team that pioneered blood group incompatible renal transplantation in Australia in the early 2000s, revolutionizing patient care and expanding access to life-saving transplants.

In his most recent role, Dr. Carroll provided critical immunological risk advice for heart, lung, and renal transplant programs across Australia. He also served as the National Clinical Lead for the Transplantation and Immunogenetics Service within the Australian Red Cross Lifeblood, guiding national strategies for transplantation and immunogenetic services.

In addition to his clinical and advisory roles, Dr. Carroll is an esteemed researcher and academic. He holds an adjunct Clinical Professor position at the University of Adelaide, Australia, and has authored over 70 peer-reviewed publications. His research, which includes leadership as a principal investigator in multiple Phase I-III clinical trials, has been published in leading journals such as JAMA and Lancet Oncology.

“Dr. Carroll’s appointment marks a significant milestone for Avivo as we continue to push the boundaries of what’s possible in organ transplantation and biomedical innovation,” said John Coleman, CEO of Avivo. “His experience and visionary leadership will be instrumental in advancing our mission to improve patient outcomes globally.”

Dr. Carroll succeeds Christopher Nguan, MD, who has served as Chief Medical Officer with distinction. Dr. Nguan played an essential role in shaping the company’s clinical strategies and advancing its pioneering technologies. Avivo extends its sincere gratitude to Dr. Nguan for his invaluable contributions and looks forward to his continued support.

About Avivo

Avivo has developed an innovative platform that enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s technology converts blood type to blood group O, universal donor type. This technology will enable healthcare providers to better prioritize patients by medical urgency, to spend less on management and logistics, and to ultimately save more lives. For more information about Avivo, please visit avivobio.com.

Media Contact:
John Coleman
CEO
Avivo Biomedical Inc.
jcoleman@avivobio.com